FIDELIO aims to train the next generation of scientists in order to tackle the challenges of diabetic bone disease from various angles and with the newest technologies available. The research programme will address different aspects of diabetic bone disease from the viewpoints of epidemiology, genetics, miRNAs, microbiome, bone biology, bone biomechanics and microstructure, preclinical and clinical research.
Early Stage Researcher project (ESR13) at TAmiRNA
miR-203a has been recently identified as a key regulator of bone formation and potential biomarker candidate for type-2 diabetic bone disease. In order to complete our understanding of the biological functions of this miRNA, you will characterize expression levels of miR-203a in different compartments of bone tissue from type-2 diabetic and nondiabetic animals obtained in collaboration with the Technical University Dresden (TUD), and apply RNAs sequencing technology in primary (like) human bone cells (osteoprogenitors and osteoclast progenitors) under ectopic up- and down-regulation of miR-203a to identify novel mRNA targets. For more information click here or get in touch
TAmiRNA specializes in technologies for profiling levels of blood-circulating microRNAs and developing multi-parametric classification algorithms (“signatures”). TAmiRNA uses these technologies to develop minimal-invasive diagnostic tests for drug development, early diagnosis and prognosis of disease, and as companion diagnostic tests to support treatment decisions.